QIAGEN reaches milestone with over 1,000 placements of EZ2 Connect sample preparation instrument

QIAGEN announced it has reached a significant milestone with over 1,000 placements of the EZ2 Connect automated sample preparation instrument, an advancement of the EZ1 instrument line.

EZ2 Connect is designed to automate the entire process of nucleic acid purification, reducing hands-on time and increasing throughput while maintaining high precision and reproducibility.

Using EZ2 Connect enables researchers to focus more on data analysis and interpretation rather than repetitive manual sample processing. The system is particularly beneficial for laboratories handling medium volumes of samples for use across a range of downstream molecular biology research applications, such as digital PCR and next-generation sequencing (NGS).

The EZ2 Connect portfolio encompasses kits and instruments which offer:

• Broad sample compatibility: kits support tissue, liquid biopsies, trace samples, cultured cells, FFPE (Formalin-Fixed Paraffin Embedded Tissue) and more.

• Various possibilities for downstream analyses: nucleic acids purified from these samples can be used for downstream analyses with technologies such as digital PCR (dPCR), quantitative PCR (qPCR) and next-generation sequencing (NGS).

• Additional instrument versions: EZ2 Connect MDx tailored for diagnostic applications and clinical labs, and EZ2 Connect FX supporting forensic scientists with dedicated human ID and forensics protocols.

• Diverse applications: EZ2 Connect supports applications such as diagnostics, genomics and cancer research, molecular epidemiology and forensics.

A kit for the isolation of RNA from blood samples and two kits for forensic applications are planned for launch in 2025 to further expand the portfolio.

QIAGEN release